Airway diseases
Respiratory critical care
Thematic poster
Clinical studies of asthma treatments
Methods :
Epidemiology, General respiratory patient care, Respiratory intensive care, Pulmonary rehabilitation, Endoscopy and interventional pulmonology, Public health, Physiology
Curcumin Improves Therapy of Moderate Partially Controlled Asthma: Placebo-controlled, single blind study
E. Jusufovic(Tuzla, Bosnia and Herzegovina)
COI
1
A long-term (2 years) efficacy and safety study of doxofylline in the treatment of asthma
M. Cazzola(Roma (RM), Italy)
COI
2
Interval Exercise Training in Poorly Controlled Asthma: Preliminary Clinical Trial Results
A. Freeman(Southampton, United Kingdom)
COI
3
Montelukast induces better control of symptoms and management of lung function, and decreased inflammation in women compared with men.
G. Spaziano(Caserta, Italy)
COI
4
Does long-term macrolide treatment reduce asthma exacerbations? An individual patient data meta-analysis
S. Hiles(New Lambton Heights, Australia)
COI
5
Towards optimal patient selection for bronchial thermoplasty treatment in severe asthma: results from the TASMA randomized trial
A. Goorsenberg(Amsterdam, Netherlands)
COI
6
Clinical phenotypes of asthmatics who require long-term use of tiotropium for asthma control: a real-world study
W. Cheng(Taichung, Taiwan)
COI
7
Lung function normalization with indacaterol/glycopyrronium/mometasone furoate in patients with asthma
K. Chapman(Toronto (ON), Canada)
COI
8
Pharmacokinetics of indacaterol, glycopyrronium and mometasone furoate following once daily inhalation as a fixed-dose combination in healthy subjects
H. Tillmann(Basel, Switzerland)
COI
9
Pharmacokinetics of indacaterol, glycopyrronium and mometasone furoate as a fixed-dose combination in Japanese and Caucasian healthy subjects
H. Tillmann(Basel, Switzerland)
COI
10
Lung function, pharmacokinetics, and tolerability of indacaterol maleate and acetate in asthma patients
S. Miller(North Dartmouth, United States)
COI
11
Variability in Blood Eosinophils: Findings from the WATCH Cohort of Difficult Asthma
A. Azim(Bournemouth (Dorset), United Kingdom)
COI
12
Influence of controller therapy with extrafine beclometasone/formoterol on the quality of life of asthma patients with cold and/or osmotic airway hyperresponsiveness
N. Perelman(Blagoveshchensk (Amur Oblast), Russian Federation)
COI
13
Free serum IgE suppression with omalizumab and clinical outcomes in asthma
14
Omalizumab in the real-world: systematic review of asthma control outcomes reported by patients
F. Nissen(Basel, Switzerland)
COI
15
The relationship between severe asthma eosinophilic phenotypes and the clinical response to benralizumab at 16 weeks
D. Jackson(London, United Kingdom)
COI
16
Durability of mepolizumab treatment response between doses
I. Pavord(Oxford (Oxfordshire), United Kingdom)
COI
17
Omalizumab reduces asthma exacerbations and oral corticosteroid use in patients with severe allergic asthma: a systematic review of observational studies
F. Nissen(Basel, Switzerland)
COI
18
Effects of Mepolizumab on symptoms, systemic and bronchial inflammation
F. Cherubino(Varese (VA), Italy)
COI
19
. . .
